ImmunoBiochem Corporation

www.immunobiochem.com

Immunobiochem Corporation is a biotechnology company committed to addressing unmet medical need in oncology through research and development of novel, targeted biological therapeutics. ImmunoBiochem is headquartered in Ontario, Canada, and draws on the vast expertise of cancer researchers and clinicians located in the biomedical hub of downtown Toronto. ImmunoBiochem has pioneered a proprietary technology to address the challenge of cancer heterogeneity in solid tumors with its tumor microenvironment-targeted antibody-drug conjugates (ADCs). ADCs comprise a novel class of potentiated biological therapeutics, combining the targeting capabilities of monoclonal antibodies with the cytotoxic properties of small molecule cancer drugs to selectively and specifically destroy cancer cells while minimizing damage to normal tissues. ADCs comprise an antibody component linked to a cytotoxic molecule via a stable linker that is uniquely engineered to deliver and release the cytotoxic payload in cancer cells. ImmunoBiochem's lead ADC candidates, IMB-202 and IMB-212, are in development for a number of solid malignancies, including the Triple-Negative Breast Cancer indication that is a significant unmet need with no biological treatment options currently available.

Read more

Reach decision makers at ImmunoBiochem Corporation

Lusha Magic

Free credit every month!

Immunobiochem Corporation is a biotechnology company committed to addressing unmet medical need in oncology through research and development of novel, targeted biological therapeutics. ImmunoBiochem is headquartered in Ontario, Canada, and draws on the vast expertise of cancer researchers and clinicians located in the biomedical hub of downtown Toronto. ImmunoBiochem has pioneered a proprietary technology to address the challenge of cancer heterogeneity in solid tumors with its tumor microenvironment-targeted antibody-drug conjugates (ADCs). ADCs comprise a novel class of potentiated biological therapeutics, combining the targeting capabilities of monoclonal antibodies with the cytotoxic properties of small molecule cancer drugs to selectively and specifically destroy cancer cells while minimizing damage to normal tissues. ADCs comprise an antibody component linked to a cytotoxic molecule via a stable linker that is uniquely engineered to deliver and release the cytotoxic payload in cancer cells. ImmunoBiochem's lead ADC candidates, IMB-202 and IMB-212, are in development for a number of solid malignancies, including the Triple-Negative Breast Cancer indication that is a significant unmet need with no biological treatment options currently available.

Read more
icon

Country

icon

City (Headquarters)

Toronto

icon

Employees

1-10

icon

Founded

2007

icon

Estimated Revenue

$5,000,000 to $10,000,000

icon

Social

  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Advisory Board Member

    Email ****** @****.com
    Phone (***) ****-****
  • Chief Executive Officer

    Email ****** @****.com
    Phone (***) ****-****
  • Director

    Email ****** @****.com
    Phone (***) ****-****
  • Advisor

    Email ****** @****.com
    Phone (***) ****-****

Technologies

(9)

Reach decision makers at ImmunoBiochem Corporation

Free credits every month!

My account

Sign up now to uncover all the contact details